Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Oxford DeLIVER research attracts 1000 patients for innovative Pearl clinical study


1000 patients have been recruited for the Pearl study within the DeLIVER programme.

Ludwig Oxford scientists participate in symposia for aspiring your scientists

Public Engagement

As part of the Scientists in Schools programme, Dr Carol Leung and Oliver Featherstone give talks to students on their work in cancer research.

Ludwig Oxford's Professor Yang Shi elected to Academy of Medical Sciences


Ludwig Oxford's Yang Shi has been announced as a Fellow of the Academy of Medical Sciences

Ludwig Oxford Principal Investigators host interns for NDM’s summer studentships

Boccellato Shi Song

Three research teams within Ludwig Institute for Cancer Research Oxford are looking to host undergraduate and Masters students as an exciting opportunity to experience active research in an Oxford University Institute.

CAPS+ method provides improved detection of cytosine modifications in double-stranded DNA

Ludwig Oxford’s Professor Chunxiao Song develops a new method, CAPS+, for improved detection of modifications to the DNA base cytosine

Lithuanian Ambassador visits Ludwig Oxford’s Skirmantas Kriaucionis


The Lithuanian Ambassador to the United Kingdom, His Excellency Mr. Eitvydas Bajarūnas, paid visit to Professor Skirmantas Kriaucionis last week at Ludwig Oxford

iASPP as a regulator of immunological tolerance


Researchers from the Lu lab identify iASPP to be a key component in the anti-tumour immune response

HIF and AHR transcription factors interact in kidney carcinomas raising the potential for effective combination therapy


Ludwig Oxford’s David Mole and Peter Ratcliffe show interaction between transcription factors HIF and AHR, indicating a combined approach to therapy may provide greater efficacy for cancer treatment.

Ludwig’s Tammie Bishop awarded Associate Professorship


Congratulations to Tammie Bishop, who is made associate professor at the University of Oxford.

Pan-cancer gene signature provides insights into HIF pathway activation


Researchers from David Mole’s and Peter Ratcliffe’s laboratories establish a HIF metagene for studying hypoxia pathways.

Professor Xin Lu featured in Ludwig's Women in Science report


Ludwig Oxford’s Professor Xin Lu recounts her experiences in Ludwig Cancer Research’s special Women in Science report.

Ludwig Oxford’s Dr Parinaz Mehdipour celebrates local young scientists

Mehdipour Public Engagement

Parinaz shared insights into her career during the Science Oxford event recognising outstanding Year 13 STEM students in Oxfordshire and Buckinghamshire

Ludwig Oxford student awarded NDM graduate student prize


Dr Tom Carroll from the Lu lab receives a Highly Commended award under the NDM overall graduate student prize

Ludwig Oxford research wins Journal for ImmunoTherapy of Cancer’s best basic tumour immunology paper of 2022

Van den Eynde

A paper on a therapeutic cancer vaccine from the Van den Eynde lab was singled out for this award celebrating excellence in scientific research.

Algebraic, geometric, and topological data analysis methods enhance systems biology model of ERK kinetics.


A mathematical analysis carried out by the Byrne group and colleagues brings new understanding to a recently published kinetic model of ERK phosphorylation.

Mechanistic insights into the ZBP1 inflammatory response

Gyrd-Hansen Lu Van den Eynde

A collaborative study, led by former Ludwig Oxford group leader Professor Mads Gyrd-Hansen, sheds light on the ZBP1-induced signalling pathway, a pathway which contributes to the viral immune response, including to SARS-CoV-2

Unexpected role of iASPP as a tumour suppressor


The Lu lab reveals that the previously characterised oncogene, iASPP, acts as a tumour suppressor in mutant RAS- and inflammation-driven skin cancers.

Two new therapeutic targets in tuft cell-like small cell lung cancer


Yang Shi’s group identify two transcriptional co-activators that are selectively important for cancer cell but not normal cell survival.

Ludwig Oxford's Yang Shi elected to National Academy of Medicine


Ludwig Cancer Research congratulates Yang Shi on one of the highest honours in the fields of health and medicine

Richard White joins Ludwig Oxford


It is with great pleasure that Ludwig Cancer Research announces that Richard White has joined the Oxford Branch of the Ludwig Institute for Cancer Research.

Load More